You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alemtuzumab

Showing 76 - 100 of 419
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Leukemia Trial in Houston (drug, other, radiation, procedure)

Completed
Has Results
  • Lymphoma
  • Leukemia
  • Houston, Texas
    UT MD Anderson Cancer Center
Sep 1, 2020

Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)

Recruiting
  • Lymphoblastic Lymphoma
  • +2 more
  • BEAM-201
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jun 2, 2023

Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Recruiting
  • Primary Immunodeficiency (PID)
  • +4 more
  • data collection
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Feb 9, 2022

Sickle Cell Disease Trial in United States (Busulfan, Fludarabine, r-ATG)

Active, not recruiting
  • Sickle Cell Disease
  • Oakland, California
  • +34 more
Sep 21, 2022

Thalassemia Trial in Houston (Busulfan, Fludarabine, Campath 1H)

Terminated
Has Results
  • Thalassemia
  • Houston, Texas
    Texas Children's Hospital
Apr 30, 2020

Organ Transplantation Trial in Atlanta (Belatacept, Sirolimus, Alemtuzumab)

Completed
Has Results
  • Organ Transplantation
  • Atlanta, Georgia
  • +1 more
Jan 30, 2020

Acute Lymphoblastic Leukemia Trial in United Kingdom (Fludarabine, Melphalan, Alemtuzumab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Birmingham, United Kingdom
  • +21 more
Oct 14, 2021

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor Trial in Memphis (drug, biological, device)

Completed
  • Ewing Sarcoma
  • +12 more
  • alemtuzumab
  • +6 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 14, 2020

Evidence of Liver Transplantation, Rejection, ALEMTUZUMAB Trial (Alemtuzumab)

Completed
Has Results
  • Evidence of Liver Transplantation
  • +2 more
  • Alemtuzumab
  • (no location specified)
Jul 1, 2019

Sickle Cell Disease Trial in Amsterdam (Engerix-B)

Recruiting
  • Sickle Cell Disease
  • Amsterdam, Netherlands
    Amsterdam Medical Centre
Jan 6, 2022

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Reduced-Intensity Conditioning Regimen
  • Myeloablative Conditioning Regimen
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Jan 4, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in United Kingdom, United States (Early Highly Effective Therapies Group,

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Highly Effective Therapies Group
  • Escalation Therapies Group
  • Aurora, Colorado
  • +30 more
Jul 22, 2022

Chronic Lymphocytic Leukemia Trial in Austria, France, Germany (Alemtuzumab)

Completed
  • Chronic Lymphocytic Leukemia
  • Alemtuzumab
  • Wien, Austria
  • +37 more
Oct 21, 2019

Chronic Granulomatous Disease, CGD Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (JSP191)

Recruiting
  • Chronic Granulomatous Disease
  • CGD
  • JSP191
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 5, 2023

Immunodeficiency Syndrome, Non-Cancer Diagnosis Trial in United States (biological, procedure, drug, other, radiation)

Completed
Has Results
  • Immunodeficiency Syndrome
  • Non-Cancer Diagnosis
  • Alemtuzumab
  • +7 more
  • Oakland, California
  • +5 more
Feb 5, 2020

Hematologic Tumors, Multiple Myeloma, Anemia, Aplastic Trial in Tucson (busulfan, and melphalan, and alemtuzumab)

Completed
Has Results
  • Hematologic Neoplasms
  • +4 more
  • busulfan, and melphalan, and alemtuzumab
  • Tucson, Arizona
    University Medical Center and UMC-North Clinic
Sep 5, 2019

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in New York (CliniMACS

Recruiting
  • Chronic Myeloid Leukemia (CML)
  • +5 more
  • CliniMACS CD34+ Reagent System
  • +8 more
  • New York, New York
    Columbia University Medical Center
Jun 17, 2020

Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies Trial in Philadelphia (RIC: Distal Campath, RIC:Intermediate

Recruiting
  • Non Malignant Diseases
  • +2 more
  • RIC: Distal Campath
  • +2 more
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Mar 8, 2022

End Stage Renal Disease Trial in Los Angeles (Tacrolimus Extended-Release Oral Capsule)

Completed
Has Results
  • End Stage Renal Disease
  • Tacrolimus Extended-Release Oral Capsule
  • Los Angeles, California
    Cedars Sinai Medical Center
Jan 7, 2022

Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease Trial in Canada,

Completed
Has Results
  • Hemophagocytic Lymphohistiocytosis
  • +5 more
  • Hematopoietic Stem Cell Transplant
  • Birmingham, Alabama
  • +21 more
Dec 6, 2022

Chronic Lymphocytic Leukemia Trial in Germany (Alemtuzumab i.v., Alemtuzumab s.c.)

Completed
  • Chronic Lymphocytic Leukemia
  • Alemtuzumab i.v.
  • Alemtuzumab s.c.
  • Cologne, Germany
  • +5 more
Jun 12, 2019

Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS:

Unknown status
  • Multiple Sclerosis
  • Alemtuzumab Injection [Lemtrada]
  • Münster, NRW, Germany
    Department of Neurology
Sep 18, 2019

Myeloid Malignancy, Bone Marrow Failure Syndrome, Transfusion-dependent Red Blood Cell (RBC) Defect Trial in San Francisco

Terminated
Has Results
  • Myeloid Malignancy
  • +5 more
  • Alemtuzumab
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Feb 25, 2020

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Sep 26, 2022

Multiple Sclerosis Trial in Boston ([F-18]PBR06)

Not yet recruiting
  • Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
Jun 10, 2019